Stock Taper
| DATE | TYPE | RATIO |
|---|---|---|
| 2018-02-14 | Reverse | 1:11 |
| 2012-11-09 | Reverse | 1:6 |
Vaxart, Inc. is a clinical-stage biotech developing oral recombinant protein vaccines, including norovirus, influenza, RSV, and COVID-19, as well as therapeutic HPV vaccines.

Vaxart is developing a clinical-stage, oral, needle-free norovirus vaccine targeting mucosal immunity, with positive Phase 1 data in 2026 and a second-generation version in development.
| Icon | PRODUCT | Q3-2025 | Q4-2025 | Q1-2026 | Q2-2026 |
|---|---|---|---|---|---|
![]() | Government Contract | $72.41M | $21.37M ▼ | $36.37M ▲ | $24.26M ▼ |
![]() | Collaboration Revenue | — | — | $11.72M | $7.72M ▼ |
![]() | Non Cash Royalty Revenue | — | $350K | $42K ▼ | $11K ▼ |
| Map | REGION | Q1-2018 | Q2-2018 |
|---|---|---|---|
![]() | JAPAN | $28K | $1K ▼ |
Overall rating: A-
| PEER | PRICE | |
|---|---|---|
RLMD | $4.33 | COMPARE |
IMUX | $15.40 | COMPARE |
UNCY | $5.26 | COMPARE |
CBUS | $1.65 | COMPARE |
FBIO | $2.77 | COMPARE |
ACRV | $2.06 | COMPARE |
CAMP | $4.15 | COMPARE |
PMVP | $1.22 | COMPARE |